Synthon Claims Sepracor Misled USPTO On Xyzal
Bolstering its bid for permission to market a generic version of allergy treatment Xyzal, Synthon Pharmaceuticals Inc. is claiming that Sepracor Inc. misled the U.S. Patent and Trademark Office when it...To view the full article, register now.
Already a subscriber? Click here to view full article